electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
04 Abril 2023 - 9:00AM
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a
commercial-stage bioelectronic medicine and wellness company, today
announced that the gammaCore Sapphire™ non-invasive vagus nerve
stimulator (nVNS) will be available for purchase by clinicians
through the Carrick Institute for Graduate Studies which provides
clinical neuroscience education.
“The Carrick Institute offers courses and
programs to help educate clinicians on the application of
functional neurology,” says President Tricia Carrick of the Carrick
Institute. “To date, the Carrick Institute has trained more than
19,000 scholars through different programs. gammaCore nVNS is a
unique therapy that can be used as yet another tool for clinicians
to practice neurorehabilitation and provide the greatest outcomes
for their patients.”
“We are excited to be working with the Carrick
Institute as we expand patient access to our therapy through
non-allopathic focused clinicians,” commented Dan Goldberger,
electroCore’s Chief Executive Officer. “The Carrick Institute has a
reputation of providing its scholars with world class clinical
neuroscience education through programs and training, and we are
excited that Carrick has chosen the gammaCore Sapphire nVNS
stimulator as a device that can be utilized as a way for sufferers
of primary headaches to find relief.”
About The Carrick
InstituteCarrick Institute has been a world leader in
clinical neuroscience education for over 40 years. Carrick
Institute offers courses to help clinicians prepare for their next
big steps in education, career, grow personally and professionally,
and transform their future.
For more information, visit
www.carrickinstitute.com.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general well-being and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About gammaCore™gammaCore™ (nVNS) is the first
non-invasive, hand-held medical therapy applied at the neck to
treat migraine and cluster headache through the utilization of a
mild electrical stimulation to the vagus nerve that passes through
the skin. Designed as a portable, easy-to-use technology, gammaCore
is self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore™ is intended to provide non-invasive vagus nerve
stimulation (nVNS) on the side of the neck for preventive treatment
of migraine and the acute treatment of pain associated with
migraine in patients 12 and older. gammaCore is also indicated for
adjunctive use for preventive treatment of cluster headache, acute
treatment of episodic cluster headache, and treatment of hemicrania
continua and paroxysmal hemicrania in adult patients. gammaCore
should not be used by people with an active implantable medical
device. Please refer to gammaCore.com or the Instructions for Use
for complete safety information, including indications,
contraindications, warnings, cautions, and instructions.
Forward-Looking StatementsThis
press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore's business
prospects and clinical and product development plans; its pipeline
or potential markets for its technologies; the timing, outcome and
impact of regulatory, clinical and commercial developments; the
Company’s business prospects through the Carrick Institute and
other new corporate accounts or other new markets and other
statements that are not historical in nature, particularly those
that utilize terminology such as "anticipates," "will," "expects,"
"believes," "intends," other words of similar meaning, derivations
of such words and the use of future dates. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to raise the additional funding needed to continue to
pursue electroCore’s business and product development plans, the
inherent uncertainties associated with developing new products or
technologies, the ability to commercialize gammaCore™, the
potential impact and effects of COVID-19 on the business of
electroCore, electroCore’s results of operations and financial
performance, and any measures electroCore has and may take in
response to COVID-19 and any expectations electroCore may have with
respect thereto, competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents electroCore
files with the SEC available at www.sec.gov.
Contact:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024